Human NK Cell Up-regulation of CD69, HLA-DR, Interferon γ Secretion and Cytotoxic Activity by Plasmacytoid Dendritic Cells is Regulated through Overlapping but Different Pathways. by Benlahrech, Adel et al.
Matthews, NC; Goodier, MR; Robey, RC; Bower, M; Gotch, FM
(2011) Killing of Kaposi’s sarcoma-associated herpesvirus-infected fi-
broblasts during latent infection by activated natural killer cells. Eu-
ropean journal of immunology, 41 (7). pp. 1958-68. ISSN 0014-2980
Downloaded from: http://researchonline.lshtm.ac.uk/40349/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/
Killing of Kaposi’s sarcoma-associated herpesvirus-
infected fibroblasts during latent infection by activated
natural killer cells
Nick C. Matthews1, Martin R. Goodier1, Rebecca C. Robey1, Mark Bower 2
and Frances M. Gotch1
1 Department of Immunology, Chelsea and Westminster Hospital, Imperial College London,
London, UK
2 Department of Oncology, Chelsea and Westminster Hospital, Imperial College London,
London, UK
Kaposi’s sarcoma-associated herpesvirus (KSHV) establishes life-long infection by evading
clearance by the host immune system. In de novo infection and lytic replication, KSHV
escapes cytotoxic T cells and NK cells through downregulation of MHC class-I and ICAM-1
molecules and associated antigens involved in forming and sustaining the immunological
synapse. However, the efficacy of such mechanisms in the context of the predominantly
latent KSHV infection reported in Kaposi’s sarcoma (KS) lesions is unclear. Using primary
dermal fibroblasts in a novel in vitro model of chronic latent KSHV infection, we generated
target cells with viral loads similar to those in spindle cells extracted from KS lesions. We
show that latently KSHV-infected fibroblasts had normal levels of MHC-class I, ICAM-1,
HLA-E and NKG2D ligand expression, were resistant to NK-cell natural cytotoxicity and
were highly susceptible to killing by cytokine-activated immunocompetent NK cells.
KSHV-infected fibroblasts expressed normal levels of IFN-cR1 and responded to exogen-
ous IFN-c by upregulating MHC class I, ICAM-1 and HLA-E and resisting activated NK-cell
killing. These data demonstrate that physiologically relevant levels of latent KSHV infec-
tion in primary cells cause limited activation of resting NK cells and confer little specific
resistance to control by activated NK cells.
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Introduction
Kaposi’s sarcoma-associated herpesvirus (KSHV) infection is
etiologically linked with the endothelial cell cancer Kaposi’s
sarcoma (KS), and with the rare B-cell lymphoproliferative
disorders primary effusion lymphoma (PEL) and multicentric
Castleman’s disease (MCD) [1–3]. KSHV exists in either a lytic or
latent state facilitating life-long infection of the host [4].
Individuals with KSHV infection have cellular and humoral
immune responses to latent and lytic KSHV antigens [5–8].
KSHV infection is predominantly latent within KS lesions with
the expression of a small number of genes by proliferating spindle
cells of lymphatic endothelial cell (LEC) phenotype [9]. While
otherwise healthy KSHV-infected individuals may remain
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asymptomatic, the risk of developing KSHV-associated diseases is
increased 20 000-fold in individuals who are immunosuppressed
by HIV-1 infection or by 500-fold in patients receiving immuno-
suppressive drug therapy following allograft transplantation
[10]. AIDS-KS is aggressive and can involve the skin, the lymph
nodes and the mucosa of the lungs and gut [3]. Disease patho-
genesis in AIDS-KS is linked to depletion of CD41 T cells and the
loss of KSHV-specific CD81 cytotoxic T lymphocyte (CTL)
responses [8], and treatment of AIDS-KS patients with highly
active antiretroviral therapy (HAART) frequently induces KS
remission [11] in association with recovery of anti-KSHV CTL
responses [6].
Many viruses express factors (HIV-1 Nef [12], CMV-US-2,
US-3, US-6, US-11 [13, 14], EBV–EBNA1 [15]) which restrict
viral clearance by interfering with MHC class I expression and
viral peptide presentation to CD81 CTLs. Early during lytic
reactivation, KSHV avoids recognition by the expression of K3
and K5 ubiquitin ligases [16, 17]. Both of these downregulate
surface expression of HLA-A and HLA-B but K3 also down-
regulates the NK-cell inhibitory ligands HLA-C and HLA-E [16].
Reduced expression of these HLA allotypes leaves the infected
host cell vulnerable to lysis by NK cells which, unlike CD81 CTLs,
are primed to kill virally infected cells without requiring prior
antigenic sensitisation [18]. To avoid such killing by NK cells,
KSHV uses K5 to reduce surface expression of ICAM-1 adhesion
molecules and the NK-cell activatory ligand MHC class I-related
chain A (MICA) [19]. Furthermore, K5 and K3 block the effect of
antiviral IFN-g by downregulating the IFN-gR1 [20]. Thus, during
lytic reactivation, KSHV effectively disables construction of the
immunological synapse between a virally infected host cell and
effector CTLs and NK cells. This effect has also been reported in
early de novo latent KSHV infection as an outcome of concurrent
lytic and latent gene expression [21, 22].
The importance of NK-cell immunity is demonstrated in the
rare incidences of naturally NK-cell-deficient individuals who are
highly vulnerable to herpesvirus infections whilst retaining
immunity to bacterial and parasitic infections, [23]. NK cells from
AIDS-KS patients failing HAART and with active KS have low
cytotoxicity against KSHV-infected body cavity B-cell lymphoma
cell (BCBL-1) targets, whereas NK cells from healthy individuals,
and from AIDS patients receiving HAART and with regressing KS,
have high cytotoxicity, suggesting that effective control of KSHV
infection in KS is linked with intact NK-cell function [24].
The extent to which KSHV-induced phenotypic changes affect
the efficiency of NK-cell recognition and kill in the context of
overall KSHV infection is unclear since previous studies have
evaluated KSHV infection and NK-cell-mediated cytotoxicity
using transfectants expressing only KSHV-K5 or K3 proteins
[25, 26], or have used transformed KSHV-infected BCBL cell lines
as target cells with no equivalent uninfected cells used as nega-
tive controls [24]. To address this issue, we generated new target
cells using primary dermal fibroblasts chronically infected with
KSHV or uninfected. Using this system, we first determined
whether chronic latent KSHV infection of primary, untransformed
cells affects surface expression of MHC class I, ICAM-1, HLA-E
and NKG2D ligands involved in NK-cell target recognition and
activation. Secondly, we investigated whether such changes in
phenotype enabled resistance to killing by NK cells. Thirdly, since
NK cells control virus replication through anti-viral cytokine
secretion, we investigated the effect of chronic latent KSHV
infection on responsiveness to IFN-g.
Results
Latent infection of dermal neonatal fibroblasts with
KSHV
To study the susceptibility of primary cells latently infected with
KSHV to NK-cell lysis, it was necessary to generate sufficient
identifiably infected cells while at the same time maintaining
viral latency. We made use of a system employing co-culture of
O-tetradecanoylphorbol 13 acetate (TPA)-activated KSHV-positive
EBV-negative BCBL-1 cells in order to infect primary cell lines whilst
avoiding the potential induction of the lytic cycle by residual TPA
associated with large-scale preparations of KSHV [27]. Furthermore,
infected primary cells were readily detected and expanded by the
use of recombinant GFP-tagged KSHV and selection using G418 as
originally used to select the BCBL-1-GFP cells [28]. In initial studies,
primary dermal vascular endothelial cells were successfully infected
with KSHV-GFP (data not shown). However, subsequent expansion
of these cells failed under selection with G418, and insufficient
numbers of identifiable infected cells were obtained to perform NK-
cell assays. We, therefore, used primary dermal fibroblasts as targets
as these can be effectively infected and expanded and are of a similar
size to primary endothelial cells with similar levels of expression of
MHC class I and ICAM-1. Overnight co-culture at a BCBL-1-
GFP:fibroblast ratio of 10:1 induced KSHV-GFP expression byo1%
of plated fibroblasts (Fig. 1A). After 14–21 days of G418 selection,
the proportion of KSHV-GFP1 fibroblasts had increased to 25–40%
with a wide (2 logs) range of GFP expression (Fig. 1B) and identical
morphology to uninfected fibroblasts.
Expanded KSHV-infected fibroblasts were confirmed to be
latently infected by punctuate nuclear latent nuclear antigen
(LANA) staining (Fig. 1C). After G418 selection, LANA was
detected in all cells indicating that both GFP– and GFP1 fibro-
blasts had been infected with recombinant virus. In contrast,
virtually all G418-treated uninfected fibroblasts were killed
within the 2- to 3-wk G418 selection period (data not shown).
KSHV viral load was measured by quantitative real-time PCR for
K5 DNA (Fig. 1D). The mean viral load for KSHV-infected fibro-
blasts was 6.571.2 copies/cell (n53) compared with 151714
copies/cell (n53) for the BCBL-1-GFP cells used to infect the
fibroblasts. Analysis of viral mRNA by quantitative RT-PCR
showed that latently infected KSHV-infected fibroblasts had very
low levels of constitutive production of mRNA encoding early
lytic cycle associated genes K3 or K5 (49725 and 5972 copies/
104 cells (n54), respectively). This waso10% of the basal levels
in BCBL-1-GFP cells (6307111 and 704765 copies/104 cells
of K3 and K5, respectively). Stimulation of KSHV-infected
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fibroblasts with TPA failed to induce K3 and K5 mRNA production
in contrast to BCBL-1-GFP cells where TPA induced a 60- and
80-fold increase in K3 and K5 mRNA production, respectively
(Fig. 1E). These data suggest that KSHV-infected fibroblasts were
predominantly latently infected with very low levels of sponta-
neous lytic cycle activity compared with BCBL-1-GFP cells.
Phenotype of KSHV-infected fibroblasts
De novo KSHV infection has been reported to cause rapid
downregulation of MHC class I, ICAM-1 and IFN-gR1 which is
thought to protect KSHV-infected cells from killing by NK cells
and cytotoxic T cells [20, 29]. Figures 2A and 2B show that
chronically KSHV-infected fibroblasts and uninfected control
fibroblasts had similar high geo-mean fluorescence levels of
MHC class I (231757 and 234779, respectively) and ICAM-1
(340765 and 3007116, respectively). Following the same
pattern, KSHV-infected fibroblasts and control uninfected fibro-
blasts had similar low levels of expression of the non-classical
MHC class I molecule HLA-E (Fig. 2C and D, 3078 and 2777,
respectively) which inhibits NK-cell activation, and IFN-gR1
(geo-mean fluorescence levels of 2677 and 2574, respectively).
These data suggest that chronic KSHV infection of fibroblasts has
no sustained effect on the expression of MHC class I, ICAM-1,
HLA-E or IFN-gR1.
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Figure 1. Latently infected primary neonatal dermal KSHV-GFP fibroblast cells generated through co-culture with BCBL-1-GFP cells. (A) Micrograph
of a single KSHV-GFP infected fibroblast 24 h after co-culture with BCBL-1-GFP cells (photographed at 200 magnification under phase-contrast
and UV fluorescence). (B) Flow cytometric analysis of GFP expression by KSHV-GFP-infected fibroblasts (grey histogram) after G418 selection
relative to uninfected fibroblasts (open histogram). (C) IFA detection of ORF 73 LANA protein in nuclei of KSHV-infected fibroblasts (photographed
at 200 magnification under phase-contrast and UV fluorescence). (A–C) are representative of five independent experiments. (D) Total cellular
KSHV viral load determined by quantitative real-time PCR analysis of K5 DNA by chronically KSHV-infected fibroblasts and BCBL-1 cells. Data are
shown as mean copies/cell7SD (n5 3). (E) Expression of KSHV K3 and K5 lytic cycle associated mRNA production in resting and TPA-stimulated
KSHV-infected fibroblasts and BCBL-1-GFP cells determined by quantitative real-time RT-PCR (qRT-PCR). KSHV-infected fibroblasts or BCBL-1-GFP
cells were stimulated with TPA before harvesting for mRNA analysis by qRT-PCR. Data shown are the mean7SD of copies of mRNA/104 cells upon
correction for cell input by qRT-PCR for GAPDH and are summarised from four experiments.
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Latently KSHV-infected cells are susceptible to killing
by activated NK cells
BCBL-1 cells have been demonstrated to be susceptible to NK-cell
lysis [24]. We therefore investigated the susceptibility of BCBL-1
cells infected with KSHV-GFP to NK-cell lysis. Only weak natural
killing of BCBL-1GFP cells was observed compared with
NK-sensitive K562 cells (Fig. 3A). Activation of NK cells with
IL-15 resulted in increased lysis of both BCBL-1-GFP cells and
K562. Figure 3B shows that both uninfected and KSHV-infected
allogeneic fibroblasts had low levels of susceptibility to natural
killing by resting NK cells even after 20 h culture. Furthermore,
KSHV-infected fibroblasts had similar high levels of susceptibility
to IL-15-activated NK cells, indicating that latent infection did not
confer significant resistance to kill. In addition to IL-15, NK cells
are stimulated by IL-2 from activated T cells [30] and by IL-12
and IFN-a from activated macrophages and dendritic cells [31].
Figure 3C shows that NK cells activated by IL-15 and IL-2 were
three-fold more potent killers of control and KSHV-infected
fibroblasts than NK cells activated with IL-12 or IFN-a. Since
human neonatal dermal fibroblasts express the apoptosis
receptors Fas [32] and TRAIL-receptor-2 [33], we examined the
expression of their respective ligands on NK cells treated with or
without cytokines. Flow cytometric analysis revealed that the
superior cytotoxicity of IL-2- and IL-15-activated NK cells against
fibroblast targets was linked with increased NK-cell expression of
Fas ligand and TRAIL ligand (Fig. 3D). However, this probably
reflected the overall enhanced cytolytic capability of IL-2- and
IL-15-activated NK cells since antibody blockade of Fas-L and
TRAIL alone and in combination with anti-LFA-1 had no
significant protective effect (Supporting Information Fig. 1). That
upregulation of Fas-L and TRAIL alone was insufficient for killing
of resting uninfected and latently KSHV-infected fibroblast targets
suggests that other mechanisms of cytolysis are involved [34].
Thus, chronic latent KSHV infection of fibroblasts confers no
specific protection against cytotoxic effects of activated NK cells.
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Figure 2. Phenotype of latently infected KSHV-GFP fibroblasts. Expression of (A) MHC class I, (B) ICAM-1, (C) HLA-E and (D) IFN-gR1 in latently
KSHV infected and passage-matched uninfected control fibroblasts. Data shown are representative of seven (for MHC class I and ICAM-1), four and
five experiments, respectively. Values inserted in the plots are y-geo-mean fluorescence. The values in square brackets [ ] are the y-geo-mean
fluorescence for the respective isotype control. The histograms on the right-hand side of each representative plot show summarised data for
control and KSHV-infected fibroblasts in terms of mean7SD geomean fluorescence for MHC class I (n5 7), ICAM-1 (n5 7), HLA-E (n5 4) and IFN-g-
R1 (n5 5).
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KSHV-infected fibroblasts express normal levels of
ligands for NKG2D
NK cells recognise and clear damaged cells through activation of
the NKG2D receptor by stress-induced ligands including the non-
classical MHC class I chain-related molecule A and B (MICA/B)
and the ULBP family. Recent data suggest that latently KSHV-
infected BCBL-1 cells are partially protected from NK cells by
downregulation of MICB through a KSHV encoded microRNA-
mediated mechanism [35]. We therefore examined the expres-
sion of MICA/B on control uninfected and KSHV-infected
fibroblasts by flow cytometry. Although high levels of expression
of MICA/B were found on HeLa cell positive controls, we could
not detect MICA/B expression on fibroblasts with or without
KSHV infection (Fig. 4A).
In an alternative approach, we used NKG2D-Fc as a probe to
detect surface expression of all NKG2D ligands. There was an
increased expression of NKG2D ligands on near-senescent
passage 18 fibroblasts compared with passage 13 fibroblasts, but
no detectable effect of chronic latent KSHV infection on NKG2D
ligand expression (Fig. 4B).
IFN-g-induced protection of KSHV-infected fibroblasts
from kill by NK cells is associated with downregulated ORF50
mRNA and upregulated MHC class I, ICAM-1 and HLA-E
expression.
Apart from direct lysis of virally infected cells, activated NK
cells can control levels of virus production by producing anti-viral
IFN-g, which also strongly upregulates MHC class I and ICAM-1
expression. However, IFN-g has also been reported to induce
KSHV lytic cycle replication [36], which downregulates these
molecules. Furthermore, IFN-g sensitises virally infected cells to
TRAIL-induced apoptosis [33]. We, therefore, investigated the
effect of IFN-g treatment on cell phenotype, KSHV lytic cycle
mRNA and susceptibility of KSHV-infected cells to killing by
activated NK cells. IFN-g induced a rapid change in both KSHV-
infected and control uninfected fibroblasts to a spindle cell type
morphology (data not shown) and a marked three-fold upregu-
lation of MHC class I, ICAM-1 and HLA-E (Fig. 5A and B). Instead
of KSHV lytic cycle induction, IFN-g significantly reduced ORF50
(the master regulator of KSHV lytic reactivation from latency)
mRNA levels (p50.04), but not K3 or K5 mRNA (Fig. 5C). IFN-g
pre-treatment strongly inhibited killing of both KSHV-infected
and control uninfected cells by IL-15-activated NK cells (Fig. 5D
and E; p50.0003 and 0.001, respectively), These data suggest
that in addition to IFN-gR1 expression, latently KSHV-infected
fibroblasts have intact or normal levels of IFN-g responsiveness,
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Figure 3. Lysis of latently infected BCBL-1-GFP cells and KSHV-GFP fibroblasts by activated NK cells. (A) Susceptibility of BCBL-1-GFP cells to lysis
by NK cells. Lysis of BCBL-1-GFP cells by resting (NK) or IL-15-activated allogeneic NK cells was determined after 4 h of culture. K562 cells were used
as a positive control. The data shown are the mean of duplicate determinations and are representative of four independent experiments.
(B) Susceptibility of latently KSHV-infected fibroblasts to natural and IL-15-activated NK cell-mediated killing. KSHV-infected fibroblasts and
uninfected fibroblasts were co-cultured with resting or activated NK cells for 18 h prior to determination of cytotoxicity. The data shown are the
mean of duplicate determinations of NK-specific kill and are representative of four independent experiments. (C) Analysis of lysis of KSHV-
infected fibroblasts by NK cells activated with IL-2, IL-12, IL-15 or IFN-a. Data shown are the mean1SD of NK-specific kill of targets (E:T ratio of 5:1)
from four separate experiments. (D) Flow cytometric analysis of Fas-L (upper panel) and TRAIL (lower panel) expression by untreated (filled grey
histogram) and cytokine-treated NK cells (open histogram). NK cells were cultured with or without the cytokines indicated for 24 h. The data
shown are representative of two analyses.
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which modulates the expression of surface antigens crucial for
mediating NK-cell activation, KSHV viral lytic gene expression
and susceptibility to killing by activated NK cells.
Discussion
Persistent KSHV infection of endothelial cells within KS lesions is
predominantly latent with low levels of lytic activity [37]. The
involvement of NK cells in controlling KS is suggested by
observations that patients with active KS have poor cytotoxicity
against K562 and KSHV-infected BCBL cell targets, and that
regression of KS in AIDS-KS patients responding to HAART is
linked to recovery of NK-cell cytotoxicity [24]. The ideal target
cell for investigating how susceptible KSHV-infected cells are to
NK-cell control would be spindle cells derived from KS lesions,
but there are two main barriers to this. First, KSHV-infected
endothelial cells are not transformed and KSHV genomes are
rapidly lost after a few passages in vitro leading to an outgrowth
of KSHV– cells [38]. Second, confirmation of KSHV infection of
KS spindles is difficult to confirm without rendering the cell
unviable for cytotoxicity studies.
In an alternative approach, we have established an in vitro
model system for studying the ability of NK cells from immuno-
competent individuals to kill primary human fibroblasts which
have been chronically latently infected with KSHV. We found that
resting NK cells exhibited only weak natural cytotoxicity against
KSHV-infected dermal fibroblasts with no additional killing being
observed over that seen when uninfected fibroblasts were used as
targets. Previous studies have demonstrated NK-cell killing of
KSHV-infected BCBL-1 PEL cells, an observation confirmed in the
current study [24]. However, in the case of such tumours it was
not possible to distinguish any potential modulating effects of
latent KSHV infection on the NK-cell response to the cell line, due
to the lack of uninfected control cells. Observations from our
model suggest that chronic latent infection of primary cells with
KSHV does not induce additional natural kill activity or prevent
cytotoxicity by cytokine-activated NK cells.
Three weeks after de novo infection, we found that surface
expression of ICAM-1, MHC-class I, HLA-E, IFN-gR1 and NKG2D-
ligands by both GFP– and GFP1 KSHV-infected cells in established
persistent latency was the same as in uninfected controls,
consistent with a lack of modulation of NK-cell cytotoxicity.
Thus, chronic latent KSHV infection of fibroblasts by
co-culture had no detectable sustained effect on basal surface
expression of antigens involved in immunological synapse
formation or ligands for NK-cell activation and inhibition. This
may reflect the situation in vivo where KSHV infection is
asymptomatic. In contrast, gene expression microarray data
derived from the nodules of AIDS-KS patients suggest that rela-
tive mRNA expression for the activating NKG2D ligands MICB
and ULBP2 is significantly increased compared with healthy skin
[39]. Our data would suggest that this is not due to the direct
effects of latent KSHV infection, but perhaps through the
advanced KS lesion being an inflamed hypoxic environment [40].
The lack of modulation of MHC class I, ICAM-1, NKG2D
ligands, IFN-gR1 and HLA-E in our primary fibroblast system is
likely due to the relatively low initial KSHV viral load obtained
through co-culture compared with the use of highly concentrated
KSHV viral supernatant, and because of the dilution of KSHV
episomes among infected daughter cells. The advantages of the
co-culture method are the reported high efficiency of cell–cell
transfer of virus (31), and most importantly its low cytopathic
effect as viable target cells are essential for sensitive NK-cell
cytotoxicity assays. Recent studies using highly sensitive multi-
spectral imaging flow cytometry confirm that downregulation of
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MHC class I and ICAM-1 following de novo KSHV infection corre-
lates with intracellular viral load [22]. It is of note that the viral
load of 6 copies/cell in KSHV-infected fibroblasts reported here is of
a similar magnitude to an estimate of 3.2 copies/cell in KS lesions
(43). In comparison, the BCBL-1-GFP cells used to initially infect
the fibroblasts had a mean viral load of 150 copies/cell and tenfold
greater production of lytic K3 and K5 mRNA. Accordingly, latently
infected BCBL-1-GFP cells had low levels of ICAM-1 and MHC class
I expression (data not shown) and were more resistant than
latently infected KSHV-Fibs to activated NK-cell killing, possibly
mediated in part through the recently described KSHV microRNA
miR-K12-7 targeting of MICB mRNA [35].
D
A
0
10
20
30
40
50
60
70
0 5 10
Fibs
Fibs+IFN-γ
KSHVfibs
KSHVFibs+IFN-γ
E:T ratio
%
 N
K-
sp
ec
ific
 k
ill 
Co
pi
es
 
m
RN
A/
10
E4
 c
e
lls
B
1
2
3
4
5
MHC Class I ICAM-1 HLA-E
Fibs
KSHV-Fibs
304 920 260 917
175 404 174 412
37 36111 134
GFP
H
LA
-E
IC
AM
-1
M
H
C 
Cl
a
ss
 I
Fo
ld
 in
cr
ea
se
 in
 
Ag
 e
xp
re
ss
io
n
C
Fibs Fibs + IFN-γ KSHV-Fibs KSHV-Fibs+IFN-γ
0
50
100
150
200
250
300
K3 K5 ORF50
Control IFN-γ
p = 0.04
0
10
20
30
40
50
60
70
80
Fibs KSHV-Fibs
Control
IFN-γ
%
 N
K-
sp
ec
ific
 k
ill
E
p = 0.001        p = 0.0003
Figure 5. IFN-g-induced upregulation of MHC class I, ICAM-1 and HLA-E and resistance to cell killing. (A) Effect of 48 h of treatment with IFN-g
(10 ng/mL) on expression of MHC class I, ICAM-1 and HLA-E by control uninfected and KSHV-infected fibroblasts. Values inserted in the plots
are y-geo-mean fluorescence values and are representative of four independent experiments. (B) Summarised data show fold increase in
IFN-g-induced upregulation of antigen by control and KSHV-infected fibroblasts. Data presented as mean7SD (n5 4). (C) Effect of IFN-g on baseline
expression of ORF50 but not KSHV K3, K5 lytic cycle associated mRNA production. KSHV-infected fibroblasts were stimulated with IFN-g for 48 h
before harvesting for mRNA analysis by qRT-PCR. Data shown are the mean7SD (n5 4) of copies of mRNA/104 cells upon correction for cell input
by qRT-PCR for GAPDH. (D) Effect of IFN-g treatment on killing by IL-15-activated NK cells. KSHV-infected fibroblasts and uninfected fibroblasts
were treated with or without IFN-g for 48 h prior to co-culture with activated NK cells for 18 h. The data shown are the mean of duplicate
determinations of NK-specific kill and are representative of four independent experiments. (E) Summarised data show the mean7SD NK-specific
kill of control and IFN-g-treated targets (E:T ratio of 5:1) from three separate experiments. Statistical significance was determined by Student’s
t-test.
Eur. J. Immunol. 2011. 41: 1958–1968Nick C. Matthews et al.1964
& 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Our data suggest that low levels of gene expression in
chronic latent KSHV infection of fibroblasts appear to confer little
protection from activated NK-cell killing. However, during de
novo KSHV infection there is concurrent expression of high
levels of latent genes and production of a selected range of lytic
factors with anti-apoptotic and immune modulating activity,
but not lytic genes coding for viral DNA synthesis or viral
structural proteins (28). Downregulation of MHC class I is critical
because high levels of production of viral antigens during this
period would render the newly infected cell highly vulnerable to
kill by CTLs. Thereafter, expression of lytic genes is progressively
reduced until only latent gene expression persists. However,
early lytic factor K5 protein can be detected up to 5 days after
initial infection potentially helping the infected host cell to escape
kill by NK cells and CTLs. Indeed, KSHV-induced ICAM-1
and MHC class I downregulation have been reported to persist for
up to 23 days in primary dermal microvascular endothelial
cells [29]. In contrast, in latently infected primary fibroblasts,
MHC class I, ICAM-1, NK-cell activatory ligands and IFN-gR1
may have been downregulated during early infection,
and normalisation of expression of these molecules may
occur under conditions of low KSHV viral copy number
and low levels of KSHV gene expression or possibly through the
upregulatory effect on MHC class I expression by KSHV
v-FLIP [39].
Although microvascular dermal endothelial cells, the natural
initial target of KSHV infection in KS, exhibit some phenotypic
and functional differences from dermal fibroblasts, such cells may
be similarly protected from cytolysis under conditions of low copy
number latent infection. Further, where NK cells are activated by
cells undergoing low levels of KSHV reactivation, our
data demonstrating normal responsiveness of latently KSHV-
infected cells to IFN-g, suggests that neighbouring cells,
latently infected with KSHV, although inhibited from activating
lytic viral replication, may be protected from NK-cell killing. This
might be through a bystander upregulation of HLA-E, which
ligates the inhibitory NKG2A–CD94 complex combined with
upregulation of HLA-C which ligates the inhibitory NK-cell
receptor CD158a/b. The role of HLA-E and HLA-C in IFN-g-
induced resistance to NK-cell killing merits further investigation
as on the other hand, NK cells from patients with chronic KS and
in healthy HCMV seropositive individuals have increased
numbers of NK cells expressing the activatory NKG2C–CD94
complex, which would be predicted to kill HLA-E expressing
targets [41, 42].
The potent cytolytic effect of activated NK cells from healthy
individuals on primary cells with low levels of chronic latent
KSHV infection may partially explain why, in immunocompetent
individuals, KSHV infection is essentially asymptomatic and with
very low viral load. In this respect, the impact of NK cells from
immunosuppressed individuals on primary cells with low levels of
KSHV viral load is of immediate interest. Cytokine-mediated
activation of NK cells by IL-15 in such immunosuppressed
patients with persistent KS, particularly during HIV-1 infection,
may be of immunotherapeutic value [43].
Materials and methods
Cells and culture
Primary human neonatal dermal fibroblasts were obtained from
Lonza (Wokingham, UK) and cultured in FGM-2 bulletkit
medium (Lonza). The source of KSHV (GFP-KSHV) was the
GFP-recombinant KSHV1, EBV–, BCBL-1 cell line KSHV152-
BCBL-1 [28]; a gift from Dr Jeff Vieira, University of Washington,
Seattle, USA. The GFP-BCBL-1 cells used had been cloned for
high GFP expression and were cultured in RPMI 1640 medium
(Invitrogen, Paisley, UK) supplemented with 10% FCS (Sigma,
Portsmouth, UK) 2 mM L-glutamine and penicillin/streptomycin
(250 mg/mL) at a density of from 5 105 to 1 106 cells/mL.
KSHV infection of fibroblasts
Passage 10 fibroblasts were cultured to 90% confluence in 24-well
plates (Costar), and co-cultured with or without washed TPA
(20 ng/mL; Sigma-Aldrich, Poole, Dorset, UK) stimulated
GFP-BCBL-1 cells [27] at a ratio of 10 GFP-BCBL-1 cells:1 fibroblast.
After 18 h co-culture, GFP-BCBL-1 cells were removed by washing
with PBD and fibroblasts recultured in FGM-2. After 4 days, G418
(250mg/mL; Sigma) was added to select out GFP-KSHV-infected
fibroblasts, which were expanded thereafter in FGM-2 bulletkit
medium in the presence of G418. KSHV infection was confirmed by
the detection of ORF 73/ LANA protein by IFA as previously
described [44]. Cells were examined under phase contrast using UV
fluorescent microscopy. Aliquots of 2 105 cells were sub-cultured
in the absence of G418 for 5 days before all experiments.
Flow cytometric analysis
MHC class I, ICAM-1, MICA/B, HLA-E, IFN-gR1 and NKG2D ligand
expression by trypsinised uninfected and KSHV-infected fibroblasts
was assessed by flow cytometry. About, 3104 cells were
harvested and stained directly with anti-HLA-ABC or ICAM-1,
conjugated to PE or APC (Pharmingen, Oxford, UK) or to MICA/B
conjugated to APC (R&D Systems, Oxford, UK). Indirect staining
for HLA-E was performed using unconjugated anti-HLA-E (clone
3D12, a gift from Dr Dan Geraghty, Fred Hutchinson Cancer
Research Centre, Seattle, WA, USA). Indirect staining for IFN-gR1
expression was performed using unconjugated anti-IFN-gR1 (Santa
Cruz Biotechnology, CA, USA). HLA-E and IFN-gR1 antigens were
detected with biotin-conjugated anti-mouse IgG1 and streptavidin-
APC (BD Pharmingen). Indirect staining for NKG2D ligand
expression was performed using NKG2D-Fc (R&D Systems) and
detected using biotin-conjugated anti-human IgG1 and streptavi-
din-APC (BD Pharmingen). Indirect staining for Fas-L and TRAIL
expression by NK cells was performed using antibodies from R&D
Systems and detected using biotin-conjugated anti-mouse IgG1 and
streptavidin-APC.
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Flow cytometry was performed with a Becton Dickinson
FACScalibur cytometer using standard CellQuestPro acquisition
software (Becton Dickinson, Mountain View, CA, USA).
Preparation of NK effector cells
NK effector cells were purified by negative selection using
the Miltenyi Biotec NK-cell isolation kit (Bergisch
Gladbach, Germany) from Ficoll Hypaque-separated PBMCs
donated by healthy adult volunteers (according to local
ethical committee approval). NK cells (purity495% CD3– and
CD561) were cultured overnight at a density of 106/mL in 24-
well plates in complete medium (RPMI 1640 medium (Invitro-
gen) supplemented with 10% human AB serum, 2 mM L-
glutamine) with or without the NK-cell activating monokines:
IL-12, IL-15 (20 ng/mL), IFN-a (1000 IU) or with IL-2 (20 ng/mL;
R&D Systems).
Colorimetric cytotoxicity assay
NK cells treated with or without cytokines were added at various
effector:target (E/T) ratios to uninfected and KSHV-infected
fibroblast target cells at a density of 1104 cells per well and
cultured in complete medium in flat-bottomed 96-well plates.
The plates were spun at 100 g for 3 min to enhance
effector–target cell contact. After 18 h of culture, the plates were
re-spun, and lactate dehydrogenase (LDH) release in harvested
supernatants was measured using the Cytotox 960 kit (Promega,
USA) according to the manufacturer’s instructions. In experi-
ments using non-adherent PEL cells and K562 cells as targets,
assays were conducted in round-bottomed 96-well plates and
cultured for 4 h before harvesting for LDH release.
Quantitative real-time PCR for KSHV viral load and
lytic K3 and K5 mRNA
KSHV viral load and viral mRNA production were assessed
by real-time quantitative PCR (Q-PCR) using self-probing
‘scorpion’ primers [45]. Total RNA was extracted from cells
using the Qiagen RNAeasy kit (Crawley, Sussex, UK) and
subjected to two rounds of DNAase digestion and reverse
transcribed into cDNA using a Prostar first strand generation
kit (Stratagene, USA). Aliquots of 2mL of cDNA template
were subjected to Q-PCR using FAM-labelled scorpion
primers (ATDBio, University of Southampton, UK). Genomic
DNA was extracted using the Qiagen DNeasy tissue kit and
subjected to Q-PCR.
The scorpion primers used were (where f is the FAM fluor-
ophore, que is the quencher and heg is the blocker):
GAPDH: forward: 50-f-CCGCGGAGGACTCATGACCACAGCC
GCGG-que-heg-GGGGCCATCCACAGT CTTCT-30; reverse;
50-GCCTCCTGCACCACCAACTG-30
K3: forward: 50-f-CCCTGTGCATCCACAGGG-que-heg-GGAG
CTCGGAAATGAGAGATTTAGA-30; reverse: 50-GAGCCAGGTGCT-
TAAACAAC-30;
K5: forward: 50-f-TCGCGGTACAGGCGCGA-que-heg-GTGGGG
AACGAGGGCATACA-30; reverse: 50-GTTAGCCAAGTGCTTAAA-
CACT-30;
ORF50: forward: 50-f-CCCGGTGGTAATTGGCCGGG-que-heg-
CATCACCGGTTCTGCTGAGA-30; reverse: 50-TACCATGGAAG
CCGGCAACA-30.
PCR conditions were as follows: a series of 46-cycle two-step
PCRs (15 s denaturation and 20 s annealing) was carried out using a
Lightcycler (Roche, USA). The final PCR reaction mixture consisted
of 2mL cDNA template, 0.5 U of Taq polymerase (Promega), 4mL of
dNTPs (4 mM; Stratagene), 0.4mL of scorpion sense and anti-sense
primers (5mM each), 2mL of reaction buffer and 2mL of 25 mM
MgCl2 (Promega). The final volume of 20mL was made up with
nuclease-free H2O.The annealing temperatures for GAPDH, K3 and
K5 were: 56, 60, 60 and 581C, respectively.
Target template generation: GAPDH and viral mRNA levels
were expressed as the number of copies detected in each sample.
This was calculated using standard curves from serial dilutions of
target template. Target template was purified PCR product
generated using regular non-scorpion-conjugated versions of the
forward primer. PCR products were purified using the QIAquick
PCR purification kit (Crawley, UK) according to the manu-
facturer’s instructions. Threshold cycle values were converted to
copies of template by reference to a standard curve created by the
LightCycler software. GAPDH was used as a reference gene to
correct for template input.
Statistical analysis
Comparisons between groups were made using the two-tailed
Student’s t-test. A value of po0.05 was considered significant.
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